Skip to main content

LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB

Publication ,  Conference
O'Connor, OA; Flinn, I; Lunning, M; Vose, J; Fowler, N; Nastoupil, L; O'Brien, S; Schreeder, MT; Patel, MR; Fenske, TS; Brander, DM; Kuhn, JG ...
Published in: HAEMATOLOGICA
June 1, 2016

Duke Scholars

Published In

HAEMATOLOGICA

ISSN

0390-6078

Publication Date

June 1, 2016

Volume

101

Start / End Page

102 / 103

Location

Copenhagen, DENMARK

Publisher

FERRATA STORTI FOUNDATION

Conference Name

21st Congress of the European-Hematology-Association

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
O’Connor, O. A., Flinn, I., Lunning, M., Vose, J., Fowler, N., Nastoupil, L., … Burris, H. A. (2016). LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. In HAEMATOLOGICA (Vol. 101, pp. 102–103). Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
O’Connor, O. A., I. Flinn, M. Lunning, J. Vose, N. Fowler, L. Nastoupil, S. O’Brien, et al. “LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB.” In HAEMATOLOGICA, 101:102–3. FERRATA STORTI FOUNDATION, 2016.
O’Connor OA, Flinn I, Lunning M, Vose J, Fowler N, Nastoupil L, et al. LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 102–3.
O’Connor OA, Flinn I, Lunning M, Vose J, Fowler N, Nastoupil L, O’Brien S, Schreeder MT, Patel MR, Fenske TS, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Burris HA. LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN NHL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2016. p. 102–103.

Published In

HAEMATOLOGICA

ISSN

0390-6078

Publication Date

June 1, 2016

Volume

101

Start / End Page

102 / 103

Location

Copenhagen, DENMARK

Publisher

FERRATA STORTI FOUNDATION

Conference Name

21st Congress of the European-Hematology-Association

Related Subject Headings

  • Immunology
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology